Stabilized uncoated particles of reversed liquid crystalline phase materials

1. A pharmaceutical composition, comprising:

a plurality of uncoated, ionically charged particles of a single thermodynamic equilibrium reversed cubic phase material, wherein said single thermodynamic equilibrium reversed cubic phase material has an anionic charge; and

a liquid comprising a polar solvent, said uncoated, ionically charged particles being stabilized in dispersion in said liquid due to a particle zeta potential created by said anionic charge, wherein said uncoated, ionically charged particles have a size of from 10 nm to 100 microns.

2. The composition of claim 1 wherein said particle zeta potential has a magnitude greater than 25 millivolts.

3. The composition of claim 1 wherein said single thermodynamic equilibrium reversed cubic phase material includes or has associated therewith at least one active pharmaceutical ingredient dissolved therein and at least one bilayer-associated second ingredient dissolved therein, and wherein at least one of said active pharmaceutical ingredient and said second ingredient has an anionic charge.

4. The composition of claim 1 wherein said anionic charge of said particle is due to the presence of at least one charged, bilayer-associated ingredient and wherein the weight ratio of the total of all the charged, bilayer-associated ingredients to the single thermodynamic equilibrium reversed cubic phase material is between 0.01:1 and 0.15:1.

5. The composition of claim 1 wherein said composition is pharmaceutically acceptable for injection in a human or animal.

6. The composition of claim 1 wherein said single thermodynamic equilibrium reversed cubic phase material is formed from at least one active ingredient dissolved therein and at least one second ingredient dissolved therein, wherein at least one of said at least one active ingredient and said at least one second ingredient has said anionic charge.

7. The composition of claim 4 wherein said charged, bilayer-associated ingredient is selected from the group consisting of albumin, casein, stearylamine, tocopherol succinate, salt of 2-ethylhexanoic acid, salt of riboflavin, salt of riboflavin phosphate, salt of oligolactic acid, sodium dodecylsulfate, benzethonium chloride, salt of gentisic acid, salt of N-acetyltryptophan, salt of tryptophan, salt of tyrosine, salt of phenylalanine, aspartic acid, cystine, salt of oxyquinoline, salt of docusate, salt of a lactic acid-glycol acid oligomer, stearic acid and other 18-carbon fatty acids including oleic, linoleic, and linolenic acids, myristyl gamma-picolinium chloride, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, benzalkonium chloride, tocopheryl dimethylaminoacetate hydrochloride, CYTOFECTIN GS™ (dioleoylphosphatidylethanolamine, CAS#2462-63-7 and dimyristylamidoglycyl-N-α-isopropoxycarbonyl-arginine dihydrochloride), 1,2-dioleoyl-sn-glycero-3-trimethylammonium-propane, dimethyldioctadecyl ammonium bromide, trimethyl aminoethane carbamoyl cholesterol iodide, O,O′-ditetradecanoyl-N-(alpha-trimethyl ammonioacetyl)diethanolamine chloride, N-[(1-(2,3-dioleyloxy)propyl)]-N—N—N-trimethylammonium chloride, N-methyl-4-(dioleyl)methylpyridinium chloride, 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide, bis[2-(11-phenoxyundecanoate)ethyl]-dimethylammonium bromide, N-hexadecyl-N-10-[O-(4-acetoxy)-phenylundecanoate]ethyl-dimethylammonium bromide, 3-beta-[N—(N′,N′-dimethylaminoethane)carbamoyl, salt of deoxycholic acid and related cholates including glycocholate.

8. The composition of claim 3 wherein said active pharmaceutical ingredient is a pharmaceutical compound selected from the group consisting of general anesthetics, local anesthetics, anticancer compounds, muscle relaxants, hypnotics, sedatives, analgesics, antipyretics, anti-inflammatories, steroids, steroidal anti-inflammatories, opiates, cannabinoids, proteins, and antibiotics including antifungals and antimicrobials.

9. The composition of claim 3 wherein said active pharmaceutical ingredient is a general anesthetic that is selected from the group consisting of propofol, eugenol, alphaxalone, alphadalone, alphadolone, eltanolone, propanidid, ketamine, etomidate, and pregnanolone.

10. The composition of claim 1 wherein said single thermodynamic equilibrium reversed cubic phase material includes a surfactant and wherein said surfactant is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, ARLATONE® G (polyoxyethylene hydrogenated castor oil or polyoxyethylene fatty glyceride, CAS#61788-85-0), TWEEN™ 85 (polyoxyethylenesorbitan trioleate, CAS#900506506), glycerol monooleate, long-chain unsaturated monoglycerides, sorbitan monooleate, zinc docusate, calcium docusate, and poloxamers with less than about 30% polyethylene glycol (PEG) groups by weight.

11. A material, which, when combined with a medium, forms a plurality of uncoated particles each with an anionic charge and comprising a single thermodynamic equilibrium reversed cubic phase material with an active dissolved therein, and wherein said uncoated particles with an anionic charge are stable in dispersion in said medium due to a particle zeta potential created by said anionic charge, wherein said uncoated, ionically charged particles have a size of from 10 nm to 100 microns.

12. The composition of claim 1 wherein said single thermodynamic equilibrium reversed cubic phase material includes a phospholipid.

13. The composition of claim 3 wherein said active pharmaceutical ingredient is etomidate.

14. The composition of claim 1 wherein said single thermodynamic equilibrium reversed cubic phase material includes a polaxamer.

15. The composition of claim 1 wherein said particle zeta potential has a magnitude greater than or equal to 30 millivolts.

16. The composition of claim 1 wherein said particle zeta potential has a magnitude greater than or equal to 45 millivolts.

17. The composition of claim 1 wherein said particle zeta potential has a magnitude greater than or equal to 55 millivolts.

18. The composition of claim 1 further comprising a targeting moiety associated with said particles.

19. The composition of claim 1 wherein said composition is pharmaceutically acceptable for topical, buccal, oral, sublingual or inhalation administration in a human or animal.

20. The composition of claim 3 wherein the active pharmaceutical ingredient is a component of said single thermodynamic equilibrium reversed cubic phase material.

21. The composition of claim 3 wherein the active pharmaceutical ingredient is preferentially located in the bilayer of the single thermodynamic equilibrium reversed cubic phase material.

22. The material of claim 11 further comprising a targeting moiety.

23. The material of claim 11 wherein said material is pharmaceutically acceptable for topical, buccal, oral, sublingual or inhalation administration in a human or animal.

24. The material of claim 11 wherein the active is etomidate.

25. The material of claim 11 wherein the active preferentially locates in the bilayer of single thermodynamic equilibrium reversed cubic phase material.

26. The composition of claim 11 wherein said particle zeta potential has a magnitude greater than or equal to 30 millivolts.

27. The composition of claim 11 wherein said particle zeta potential has a magnitude greater than or equal to 45 millivolts.

28. The composition of claim 11 wherein said particle zeta potential has a magnitude greater than or equal to 55 millivolts.

29. The material of claim 11 wherein said material is pharmaceutically acceptable for injection in a human or animal.